May 25, 2016
Otsuka Pharmaceutical Co., Ltd.
"Neupro® Patch", a Dopaminergic, Anti-Parkinsonian Drug,
Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"
Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Tatsuo Higuchi) announces that "Neupro Patch" (generic name: rotigotine), a treatment for Parkinson's disease, will become available in Japan from June 1 with an additional new dosage amount, "Neupro Patch 18 mg".
"Neupro Patch", a therapeutic agent for Parkinson's disease and Restless Legs Syndrome*1, was launched in Japan in February 2013 and is the only transdermal dopamine agonist*2 formulation available in the world. "Neupro Patch" is applied to the skin simply and easily, just once daily, because it is a sustained release formulation that maintains blood drug concentrations and stable efficacy over a 24-hour period.
- 1Dopamine agonists work by binding to and stimulating dopamine receptors
- 2Symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults
Information in this news release was current as of the original release date.